a*****1
发帖数: 3134 | 1 不会破产。他的药治T315I，没有别的药。要想Beat Gleevec是不可能的了，但要下架
也不会。
Mostly like case is that they will reuse the testing kit from MolecularMD to
confirm T315I before use.
The good news is the the kit was there and easy to relaunch/activate it. It
is a much easier case than Tysabri because the diagnostic kit is available.
Also it is a lot easier to deal with thrombosis (Asparin maybe?) than lethal
virus that has no cure. Also people with T315I are dying and it is an acute
case, while MS was a chronic case. My be... 阅读全帖 |
|
a*****1
发帖数: 3134 | 2 不会破产。他的药治T315I，没有别的药。要想Beat Gleevec是不可能的了，但要下架
也不会。
Mostly like case is that they will reuse the testing kit from MolecularMD to
confirm T315I before use.
The good news is the the kit was there and easy to relaunch/activate it. It
is a much easier case than Tysabri because the diagnostic kit is available.
Also it is a lot easier to deal with thrombosis (Asparin maybe?) than lethal
virus that has no cure. Also people with T315I are dying and it is an acute
case, while MS was a chronic case. My be... 阅读全帖 |
|
s******i
发帖数: 350 | 3 http://www.news-medical.net/news/20120618/Updated-data-from-ARI
"The pivotal PACE trial data show robust anti-leukaemic activity of
ponatinib in patients with CML at all stages, who are resistant or
intolerant to dasatinib or nilotinib, or who have the T315I mutation, a rare
form of CML which has no available treatment options," said Jane F.
Apperley, professor and chair, Department of Haematology at the Imperial
College, and the chief of service, Clinical Haematology, at the Imperial
College He... 阅读全帖 |
|
i********i
发帖数: 329 | 4 我觉得可能性不大，对T315I mutation而言，只有这药可以治。即使是百分百几率有
side effect，也比立刻死掉好吧。不少患者已经用药好几年了。 |
|
M***n
发帖数: 5815 | 5 ☆─────────────────────────────────────☆
iolosoeisi (Quentin) 于 (Fri Oct 18 10:28:46 2013, 美东) 提到:
公司有3亿多cash，一个至少是三线的药，现在市值不到5亿。。。这就是市场信心丧失
的结果吧。。。
☆─────────────────────────────────────☆
able101 (able101) 于 (Fri Oct 18 10:34:29 2013, 美东) 提到:
What if that drug is pull off the market?
It is possible because it was conditional approval which required additional
trial. I would say 50/50.
If pull off the market, another 60% drop is likely.
☆─────────────────────────────────────☆
ioloso... 阅读全帖 |
|
